文献速递生殖医学妇科

GnRH激动剂联合芳香化酶抑制剂预处理后冻胚移植的活产率

Gonadotrophin releasing hormone agonist-aromatase inhibitor pretreatment before frozen embryo transfer in patients with endometriosis, adenomyosis, or both.
PubMed 文献 · Reprod Biomed Online · 2026-09-21

PRET-FET与显著更高的活产 odds 相关(OR 26.7,95%CI 9.48-75.0,P<0.001),结论需前瞻性研究验证。

要点

  • PRET-FET与常规FET相比活产 odds 显著升高(OR 26.7,95%CI 9.48-75.0)
  • 适用于至少一次常规FET失败的内异症/腺肌症患者
  • 常规周期中75%(119/159)采用激素替代治疗方案

核心结论

  • 在至少一次常规冻胚移植失败的内异症和/或腺肌症患者中,GnRH激动剂联合芳香化酶抑制剂预处理与显著更高的活产 odds 相关。

研究设计与样本

  • 多中心回顾性队列研究,2018至2024年在美国西北大学、丹麦Skive大学生育诊所和意大利IVI罗马中心开展。
  • 采用广义估计方程模型(可交换相关结构)并校正预设协变量(含中心和胚胎质量)。

主要发现

  • PRET-FET组活产 odds 显著高于常规FET组(OR 26.7,95%CI 9.48-75.0,P<0.001)。
  • 常规周期中75%(119/159)采用激素替代治疗控制或程序化周期方案。

关键数值与推荐

  • 干预方案PRET-FET为内膜准备前接受2个月GnRH激动剂治疗,同时或随后使用芳香化酶抑制剂。
  • 主要结局为每周期活产率。
  • 加权分析采用与患者报告总周期数成反比的逆权重。

临床怎么用

  • 对于内异症和/或腺肌症且至少一次常规FET失败的患者,可考虑GnRH激动剂联合芳香化酶抑制剂预处理方案。
  • 该方案的选择应结合患者个体情况,并告知证据来自回顾性研究。

局限性

  • 回顾性队列设计,存在选择偏倚和混杂可能。
  • 作者指出需前瞻性研究确认疗效并明确理想候选人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does pretreatment with a gonadotrophin releasing hormone (GnRH) agonist and an aromatase inhibitor (PRET) improve live birth rates in individuals with endometriosis, adenomyosis, or both, undergoing frozen embryo transfer (FET) after one or more previously failed conventional cycles? DESIGN: Multicentre retrospective cohort study of FET cycles conducted between 2018 and 2024 at Northwestern University, USA, University Fertility Clinic, Skive, Denmark and IVI Rome, Italy. Eligible individuals had endometriosis, adenomyosis and one or more previously failed conventional FET, or all. The intervention (PRET-FET) consisted of 2 months of GnRH agonist treatment concomitant with, or followed by, aromatase inhibitor treatment before endometrial preparation. The primary outcome was live birth per cycle. Generalized estimating equation models were fitted with an exchangeable correlation structure to account for multiple cycles per patient; selected models adjusted for pre-specified covariates (including site and embryo quality). Weighted analyses used inverse weights proportional to the total number of reported cycles per patient. RESULTS: Fifty-one patients across three centres (Northwestern n = 22; University Fertility Clinic n = 17; IVI Rome n = 12) contributed 217 FET cycles: 159 conventional FET cycles and 58 PRET-FET cycles. Most conventional cycles used a hormone replacement therapy, controlled or programmed cycle protocol (119/159 [75%]). Compared with conventional FET, PRET-FET was associated with significantly higher odds of live birth (OR 26.7, 95% CI 9.48 to 75.0; P < 0.001). CONCLUSIONS: GnRH agonist-aromatase inhibitor pretreatment was associated with significantly higher live birth odds among individuals with endometriosis, adenomyosis, or both, undergoing FET after one or more previously failed conventional cycles. Prospective studies are needed to confirm efficacy and define ideal candidates for this protocol.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Francone NO, Bulun SE, Ma Y, et al. Gonadotrophin releasing hormone agonist-aromatase inhibitor pretreatment before frozen embryo transfer in patients with endometriosis, adenomyosis, or both. Reprod Biomed Online. 2026. PMID: 42892070. doi:10.1016/j.rbmo.2026.105982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。